Schedule 13G ownership disclosure

Apellis Pharmaceuticals Inc

Common Stock · CUSIP: 03753U106

Event date: 2025-09-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • EcoR1 Capital, LLC

    Shares: 3,447,156.00 · Class: 2.7%

  • Oleg Nodelman

    Shares: 3,447,156.00 · Class: 2.7%

  • EcoR1 Capital Fund Qualified, L.P.

    Shares: 3,219,256.00 · Class: 2.5%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000935836-25-000697
Form type
SCHEDULE 13G/A
Filer
Apellis Pharmaceuticals, Inc.
CIK
CIK 1492422
Filed
Nov 14, 2025
Reporting period
Sep 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub